Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry

dc.contributor.authorNarváez García, Francisco Javier
dc.contributor.authorEAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology)
dc.date.accessioned2018-11-08T12:55:06Z
dc.date.available2018-11-08T12:55:06Z
dc.date.issued2015-07-01
dc.date.updated2018-11-08T12:55:06Z
dc.description.abstractThis article estimates the frequency of cardiovascular (CV) events that occurred after diagnosis in a large Spanish cohort of patients with systemic lupus erythematosus (SLE) and investigates the main risk factors for atherosclerosis. RELESSER is a nationwide multicenter, hospital-based registry of SLE patients. This is a cross-sectional study. Demographic and clinical variables, the presence of traditional risk factors, and CV events were collected. A CV event was defined as a myocardial infarction, angina, stroke, and/or peripheral artery disease. Multiple logistic regression analysis was performed to investigate the possible risk factors for atherosclerosis. From 2011 to 2012, 3658 SLE patients were enrolled. Of these, 374 (10.9%) patients suffered at least a CV event. In 269 (7.4%) patients, the CV events occurred after SLE diagnosis (86.2% women, median [interquartile range] age 54.9 years [43.2-66.1], and SLE duration of 212.0 months [120.8-289.0]). Strokes (5.7%) were the most frequent CV event, followed by ischemic heart disease (3.8%) and peripheral artery disease (2.2%). Multivariate analysis identified age (odds ratio [95% confidence interval], 1.03 [1.02-1.04]), hypertension (1.71 [1.20-2.44]), smoking (1.48 [1.06-2.07]), diabetes (2.2 [1.32-3.74]), dyslipidemia (2.18 [1.54-3.09]), neurolupus (2.42 [1.56-3.75]), valvulopathy (2.44 [1.34-4.26]), serositis (1.54 [1.09-2.18]), antiphospholipid antibodies (1.57 [1.13-2.17]), low complement (1.81 [1.12-2.93]), and azathioprine (1.47 [1.04-2.07]) as risk factors for CV events. We have confirmed that SLE patients suffer a high prevalence of premature CV disease. Both traditional and nontraditional risk factors contribute to this higher prevalence. Although it needs to be verified with future studies, our study also shows-for the first time-an association between diabetes and CV events in SLE patients.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec669962
dc.identifier.issn0025-7974
dc.identifier.pmid26200625
dc.identifier.urihttps://hdl.handle.net/2445/125907
dc.language.isoeng
dc.publisherLippincott, Williams & Wilkins. Wolters Kluwer Health
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1097/MD.0000000000001183
dc.relation.ispartofMedicine, 2015, vol. 94, num. 29, p. e1183
dc.relation.urihttps://doi.org/10.1097/MD.0000000000001183
dc.rightscc-by (c) Narváez García, Francisco Javier et al., 2015
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationLupus eritematós
dc.subject.classificationInfart de miocardi
dc.subject.classificationMalalties cardiovasculars
dc.subject.classificationArterioesclerosi
dc.subject.otherLupus erythematosus
dc.subject.otherMyocardial infarction
dc.subject.otherCardiovascular diseases
dc.subject.otherArteriosclerosis
dc.titleCardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
669962.pdf
Mida:
231.18 KB
Format:
Adobe Portable Document Format